CHAMBERLAIN NR 565 PHARMACOTHERAPEUTICS WEEK 1 QUIZ
2026/2027 | 20 QUESTIONS | VERIFIED SOLUTIONS
100% CORRECT FRAMEWORK | GRADED A+
Course: NR 565 – Pharmacotherapeutics for Primary Care
Focus: Pharmacokinetics, Pharmacodynamics, Prescription Writing, DEA Regulations, Medication Safety
Aligned with: NGN Clinical Judgment Model, APRN Scope of Practice
DOMAIN 1: PHARMACOKINETICS FUNDAMENTALS
1. A patient with cirrhosis is prescribed a medication metabolized by the liver. Which pharmacokinetic
phase is most significantly affected?
A) Absorption
B) Distribution
C) C) Metabolism
D) Excretion
Cirrhosis impairs hepatic enzyme function, significantly reducing first-pass metabolism and increasing bioavailability
of drugs metabolized by the liver.
2. A drug with a half-life of 6 hours reaches steady-state in approximately:
A) 6 hours
B) B) 24-30 hours
C) 48 hours
D) 72 hours
Steady-state is achieved after 4-5 half-lives. For a 6-hour half-life: 4.5 × 6 = 27 hours (rounded to 24-30 hours).
3. Which route of administration has the highest first-pass effect?
A) Intravenous
B) B) Oral
C) Subcutaneous
D) Topical
Oral medications undergo extensive first-pass hepatic metabolism, reducing bioavailability compared to other routes.
4. A patient on dialysis is prescribed a renally excreted drug. The APRN should:
A) Increase the dose
B) B) Reduce dose or extend dosing interval
C) No adjustment needed
D) Switch to hepatic metabolism
Dialysis removes renally excreted drugs, requiring dose reduction or extended intervals to prevent accumulation and
toxicity.
5. Bioavailability is defined as:
A) Volume of distribution
B) B) Fraction of unchanged drug reaching systemic circulation
C) Rate of drug elimination
D) Protein binding percentage
Bioavailability (F) = (AUCoral ÷ AUCIV) × 100%, representing the fraction reaching systemic circulation unchanged.
DOMAIN 2: PHARMACODYNAMICS PRINCIPLES
6. A drug with high efficacy but low potency:
A) Cannot achieve therapeutic effect
B) B) Requires higher doses but achieves maximum effect
C) Is unsafe to prescribe
D) Has low therapeutic index
Low potency means higher doses needed, but high efficacy means maximum therapeutic effect achievable at sufficient
doses.
7. Which best describes a competitive antagonist?
A) Irreversibly binds receptor
B) B) Reversibly binds receptor, can be overcome by increasing agonist
2026/2027 | 20 QUESTIONS | VERIFIED SOLUTIONS
100% CORRECT FRAMEWORK | GRADED A+
Course: NR 565 – Pharmacotherapeutics for Primary Care
Focus: Pharmacokinetics, Pharmacodynamics, Prescription Writing, DEA Regulations, Medication Safety
Aligned with: NGN Clinical Judgment Model, APRN Scope of Practice
DOMAIN 1: PHARMACOKINETICS FUNDAMENTALS
1. A patient with cirrhosis is prescribed a medication metabolized by the liver. Which pharmacokinetic
phase is most significantly affected?
A) Absorption
B) Distribution
C) C) Metabolism
D) Excretion
Cirrhosis impairs hepatic enzyme function, significantly reducing first-pass metabolism and increasing bioavailability
of drugs metabolized by the liver.
2. A drug with a half-life of 6 hours reaches steady-state in approximately:
A) 6 hours
B) B) 24-30 hours
C) 48 hours
D) 72 hours
Steady-state is achieved after 4-5 half-lives. For a 6-hour half-life: 4.5 × 6 = 27 hours (rounded to 24-30 hours).
3. Which route of administration has the highest first-pass effect?
A) Intravenous
B) B) Oral
C) Subcutaneous
D) Topical
Oral medications undergo extensive first-pass hepatic metabolism, reducing bioavailability compared to other routes.
4. A patient on dialysis is prescribed a renally excreted drug. The APRN should:
A) Increase the dose
B) B) Reduce dose or extend dosing interval
C) No adjustment needed
D) Switch to hepatic metabolism
Dialysis removes renally excreted drugs, requiring dose reduction or extended intervals to prevent accumulation and
toxicity.
5. Bioavailability is defined as:
A) Volume of distribution
B) B) Fraction of unchanged drug reaching systemic circulation
C) Rate of drug elimination
D) Protein binding percentage
Bioavailability (F) = (AUCoral ÷ AUCIV) × 100%, representing the fraction reaching systemic circulation unchanged.
DOMAIN 2: PHARMACODYNAMICS PRINCIPLES
6. A drug with high efficacy but low potency:
A) Cannot achieve therapeutic effect
B) B) Requires higher doses but achieves maximum effect
C) Is unsafe to prescribe
D) Has low therapeutic index
Low potency means higher doses needed, but high efficacy means maximum therapeutic effect achievable at sufficient
doses.
7. Which best describes a competitive antagonist?
A) Irreversibly binds receptor
B) B) Reversibly binds receptor, can be overcome by increasing agonist
